Biolase (NASDAQ: BIOL)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.680 | -0.770 | -0.0900 | ||||
REV | 9.010M | 10.166M | 1.156M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Bluejay Diagnostics (NASDAQ:BJDX), Venus Concept (NASDAQ:VERO), Talis Biomedical (NASDAQ:TLIS), Tivic Health Systems (NASDAQ:TIVC) and Motus GI Hldgs (NASDAQ:MOTS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Friday, May 20, 2022. The analyst firm set a price target for 12.00 expecting BIOL to rise to within 12 months (a possible 162.01% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $4.58 last updated July 1, 2022, 8:00 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.